LAEVOROC ONCOLOGY NEWS

Laevoroc Oncology Unveils Immunology Subsidiary with CSO Shanta Bantia to Develop PNP Inhibitor for Eradication of Relapsed Leukemia Laevoroc Immunology formed to focus on development of a highly potent Purine...

In Vivo interview with our CEO, Thomas Mehrling, where he presented Laevoroc Oncology’s three-pronged strategy to off-set risk and provide greater choice to future partners in supporting Laevoroc’s development of...

Zug, Switzerland, 11 May 2021: Laevoroc Oncology (‘Laevoroc’ or ‘the company’), a privately owned, Swiss oncology development group of companies, launched today announcing successful completion of seed financing with private...